Item 1.01 Entry into a Material Definitive Agreement.
On November 9, 2020, FibroGen, Inc. ("FibroGen") entered into a Master Services
Agreement (the "MSA") with Samsung Biologics Co., Ltd. ("Samsung"), pursuant to
which Samsung will provide FibroGen with certain biologics manufacturing
services in accordance with one or more product specific agreements.
The MSA shall remain in effect for so long as a product specific agreement is in
effect. The MSA contains standard termination clauses for material breach and
insolvency, as well as standard indemnification obligations of FibroGen and of
Samsung.
In connection with the MSA, on November 9, 2020, FibroGen and Samsung entered
into a product specific agreement (the "PSA") for the manufacturing and supply
of pamrevlumab drug substance, for clinical and commercial use. The PSA contains
product purchase and manufacturing commitments on the part of FibroGen and
Samsung, respectively, over the next two years, invoiced on a per-batch basis,
as well as technology transfer and other related services. The PSA contains
customary limitations on liability, and performance of services thereunder is
subject to the terms of the MSA.
The foregoing description of the MSA and PSA are not complete descriptions
thereof, and are qualified in their entirety by reference to the full text of
the MSA and PSA, which will be filed with the Securities and Exchange Commission
as exhibits to FibroGen's Annual Report on Form 10-K for the year ending
December 31, 2020.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
FIBROGEN, INC. 
